ATAD3A and nervous system disorder: Therefore, our research findings provide insights into the pathogenesis of AD and demonstrate that ATAD3A oligomerization is a potential therapeutic target for the treatment of AD and other neurological disorders associated with MAM hyperconnectivity and cholesterol disturbance.